A Phase 4 interventional study of DOTAREM in Magnetic Resonance Imaging, sponsored by Guerbet. Completed at 9 sites in 4 countries. Open to participants aged Up to 2 Years. Per ClinicalTrials.gov, last updated 2017-03-09.
Sponsored by Guerbet · Phase 4, Interventional, and Diagnostic
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The main purpose of the study is to evaluate the pharmacokinetics of DOTAREM® in the body of children aged less than 2 years thanks to several blood samples (3 ml in total) taken following the administration of DOTAREM®.
DOTAREM® is a contrast agent commonly used for enhancement of Magnetic Resonance Imaging (MRI) to potentially improve the quality of the images and help the diagnosis. Children aged less than 2 years scheduled to undergo routine gadolinium-enhanced MRI of any body region may take part in the study. In this case they will receive DOTAREM®, a solution injected at the standard dose of 0.2mL/kg (0.1 mmol/kg) of body weight.
Guerbet is the lead sponsor of 42 studies on the registry; 2 are open to participants now.
Of its 8 completed or terminated interventional studies of FDA-regulated products, 7 (88%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: DOTAREM
Single intravenous injection of 0.1 mmol/kg body weight
Also known as: gadoterate meglumine
Area Under the Curve of DOTAREM in Plasma
Pharmacokinetics interpretation was performed using a pharmacokinetic population modelling approach. DOTAREM concentrations in plasma were analyzed using a validated LC-MS/MS method. Area under the curve was determined from typical and individual DOTAREM concentration-time profiles.
Time frame: Blood samples were collected during 3 time windows: 15 min to 60 min, 2 hours to 4 hours and 6 hours to 8 hours post-injection
Rate Constant of the Terminal Phase of DOTAREM
Pharmacokinetics interpretation was performed using a pharmacokinetic population modelling approach. DOTAREM concentrations in plasma were analyzed using a validated LC-MS/MS method. Rate constant of the terminal phase was determined from typical and individual DOTAREM concentration-time profiles.
Time frame: Blood samples were collected during 3 time windows: 15 min to 60 min, 2 hours to 4 hours and 6 hours to 8 hours post-injection
Terminal Elimination Half-life of DOTAREM From Plasma
Pharmacokinetics interpretation was performed using a pharmacokinetic population modelling approach. DOTAREM concentrations in plasma were analyzed using a validated LC-MS/MS method. Terminal elimination half-life was determined from typical and individual DOTAREM concentration-time profiles.
Time frame: Blood samples were collected during 3 time windows: 15 min to 60 min, 2 hours to 4 hours and 6 hours to 8 hours post-injection
Total Clearance of DOTAREM From Plasma
Pharmacokinetics interpretation was performed using a pharmacokinetic population modelling approach. DOTAREM concentrations in plasma were analyzed using a validated LC-MS/MS method. Total clearance was determined from typical and individual DOTAREM concentration-time profiles.
Time frame: Blood samples were collected during 3 time windows: 15 min to 60 min, 2 hours to 4 hours and 6 hours to 8 hours post-injection
Volume of Distribution of DOTAREM at Steady State
Pharmacokinetics interpretation was performed using a pharmacokinetic population modelling approach. DOTAREM concentrations in plasma were analyzed using a validated LC-MS/MS method. Volume of distribution at steady state was determined from typical and individual DOTAREM concentration-time profiles.
Time frame: Blood samples were collected during 3 time windows: 15 min to 60 min, 2 hours to 4 hours and 6 hours to 8 hours post-injection
Simulated Plasma Concentration of DOTAREM
Pharmacokinetics interpretation was performed using a pharmacokinetic population modelling approach. DOTAREM concentrations in plasma were analyzed using a validated LC-MS/MS method.
Time frame: at 10 and 20 min post-injection
MRI Lesion Visualization at Subject Level
Lesion visualization was assessed on up to five most representative lesions per subject based on scoring of 3 co-endpoints: * border delineation (based on a 3-point scale where 1=none; 2=moderate and 3=clear and complete) * internal morphology (based on a 3-point scale where 1=poorly visible; 2=moderately visible and 3=sufficiently visible) * contrast enhancement (based on a 3-point scale where 1=none; 2=weak and 3=clear and bright) For each co-endpoint, a sum of scores was calculated at subject level as follows: sum of scores = score of the lesion 1 (+ score of the lesion 2 + score of the lesion 3 + score of the lesion 4 + score of the lesion 5, when applicable)
Time frame: Pre-injection and post-injection (estimated between 5 and 20 minutes after injection)
A total of 51 children aged less than 2 years were recruited in 4 countries: Austria, France, Hungary and Poland.
| Milestone | DOTAREM |
|---|---|
| Started | 51 |
| Completed | 45 |
| Not completed | 6 |
| Withdrew: Adverse event | 2 |
| Withdrew: Withdrawal by subject | 2 |
| Withdrew: Age group completed | 2 |
Pharmacokinetics interpretation was performed using a pharmacokinetic population modelling approach. DOTAREM concentrations in plasma were analyzed using a validated LC-MS/MS method. Area under the curve was determined from typical and individual DOTAREM concentration-time profiles.
| hour.µmol/L | DOTAREM |
|---|---|
| Area Under the Curve of DOTAREM in Plasma | 1591.1 (981.43 to 2841) |
Pharmacokinetics interpretation was performed using a pharmacokinetic population modelling approach. DOTAREM concentrations in plasma were analyzed using a validated LC-MS/MS method. Rate constant of the terminal phase was determined from typical and individual DOTAREM concentration-time profiles.
| hour-1 | DOTAREM |
|---|---|
| Rate Constant of the Terminal Phase of DOTAREM | 0.5117 (0.2288 to 0.7824) |
Pharmacokinetics interpretation was performed using a pharmacokinetic population modelling approach. DOTAREM concentrations in plasma were analyzed using a validated LC-MS/MS method. Terminal elimination half-life was determined from typical and individual DOTAREM concentration-time profiles.
| hour | DOTAREM |
|---|---|
| Terminal Elimination Half-life of DOTAREM From Plasma | 1.3545 (0.8859 to 3.0291) |
Pharmacokinetics interpretation was performed using a pharmacokinetic population modelling approach. DOTAREM concentrations in plasma were analyzed using a validated LC-MS/MS method. Total clearance was determined from typical and individual DOTAREM concentration-time profiles.
| L/hour per kg | DOTAREM |
|---|---|
| Total Clearance of DOTAREM From Plasma | 0.0602 (0.0352 to 0.1019) |
Pharmacokinetics interpretation was performed using a pharmacokinetic population modelling approach. DOTAREM concentrations in plasma were analyzed using a validated LC-MS/MS method. Volume of distribution at steady state was determined from typical and individual DOTAREM concentration-time profiles.
| L/kg | DOTAREM |
|---|---|
| Volume of Distribution of DOTAREM at Steady State | 0.0473 (0.0273 to 0.1597) |
Pharmacokinetics interpretation was performed using a pharmacokinetic population modelling approach. DOTAREM concentrations in plasma were analyzed using a validated LC-MS/MS method.
| µmol/L | DOTAREM |
|---|---|
| Simulated concentration at 10 min | 320.92 (45.223 to 2857) |
| Simulated concentration at 20 min | 275.67 (47.048 to 1565.1) |
Lesion visualization was assessed on up to five most representative lesions per subject based on scoring of 3 co-endpoints: * border delineation (based on a 3-point scale where 1=none; 2=moderate and 3=clear and complete) * internal morphology (based on a 3-point scale where 1=poorly visible; 2=moderately visible and 3=sufficiently visible) * contrast enhancement (based on a 3-point scale where 1=none; 2=weak and 3=clear and bright) For each co-endpoint, a sum of scores was calculated at subject level as follows: sum of scores = score of the lesion 1 (+ score of the lesion 2 + score of the lesion 3 + score of the lesion 4 + score of the lesion 5, when applicable)
| units on a scale | Pre-contrast | Pre- + Post-contrast |
|---|---|---|
| Sum of scores of lesion border delineation | 4.3 ± 3.7 | 5.1 ± 4.0 |
| Sum of scores of internal morphology | 4.3 ± 3.9 | 5.2 ± 4.3 |
| Sum of scores of contrast enhancement | 1.9 ± 1.5 | 5.0 ± 4.5 |
Collected over Adverse Events were collected from informed consent signature to the end of the study (7+/-1 day after DOTAREM administration). Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| DOTAREM | — | 1/45 (2.2%) | 12/45 (26.7%) |
| Event | DOTAREM |
|---|---|
| AnaemiaBlood and lymphatic system disorders | 1/45 |
| PyrexiaGeneral disorders | 1/45 |
| Upper respiratory tract infectionInfections and infestations | 1/45 |
| Event | DOTAREM |
|---|---|
| PyrexiaGeneral disorders | 5/45 |
| LeukopeniaBlood and lymphatic system disorders | 2/45 |
| Device difficult to useGeneral disorders | 1/45 |
| FatigueGeneral disorders | 1/45 |
| BronchitisInfections and infestations | 1/45 |
| InfectionInfections and infestations | 1/45 |
| NasopharyngitisInfections and infestations | 1/45 |
| RhinitisInfections and infestations | 1/45 |
| TonsillitisInfections and infestations | 1/45 |
| Urinary tract infectionInfections and infestations | 1/45 |
51 pediatric subjects were included in the study. 4 subjects could not be randomized due to consent withdrawal (n=1), adverse event (n=1) or other reason (n=2). 2 subjects did not receive DOTAREM due to consent withdrawal for 1 subject and adverse event for the second subject.
| Age, Continuous(months) | DOTAREM |
|---|---|
| Mean | 9.9 ± 7.4 |
| Age, Customized(Participants) | DOTAREM |
|---|---|
| <1 month | 5 |
| 1 to 3 months | 9 |
| >3 months to <24 months | 31 |
| Sex: Female, Male(Participants) | DOTAREM |
|---|---|
| Female | 23 |
| Male | 22 |
| Region of Enrollment(participants) | DOTAREM |
|---|---|
| Austria | 3 |
| Hungary | 9 |
| Poland | 29 |
| France | 4 |
The record gives a start of Mar 2015, a primary completion of Oct 2015 and a completion of Oct 2015. It does not say whether these dates are actual or estimated.
Results were first posted in Mar 2017, 1 year 5 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Gadoterate meglumine